OCM
VRDN icon

Orion Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Orion Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-200
Closed -$3.5K – 507
2024
Q1 		$3.5K Hold
200
– – ﹤0.01% 441
2023
Q4 		$4.36K Hold
200
– – ﹤0.01% 433
2023
Q3 		$3.07K Buy
+200
New +$3.81K ﹤0.01% 438

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Orion Capital Management's VRDN Position: Q2 2024 in Review

Orion Capital Management sold out of Viridian Therapeutics (VRDN) in Q2 2024, closing a stake of 200 shares — an estimated $3.5K sold.

Orion Capital Management first reported a position in VRDN in Q3 2023 and held it in 3 quarters. The position peaked at $4.36K in Q4 2023. 138 funds tracked by Wall St. Rank hold VRDN as of Q2 2024.

  • Orion Capital Management reported no remaining Viridian Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Orion Capital Management sold 200 Viridian Therapeutics shares in Q2 2024, an estimated $3.5K.
  • Orion Capital Management first reported a position in Viridian Therapeutics in Q3 2023 and held it in 3 quarters.
  • Orion Capital Management's Viridian Therapeutics position peaked at $4.36K in Q4 2023.
  • 138 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2024.

Based on Orion Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.